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Abstract 
Purpose: To develop mucoadhesive tablets containing miconazole (MCZ) for the treatment of 
oropharyngeal candidiasis, using chitosan and hydroxypropyl methylcellulose (HPMC) as 
mucoadhesive polymers. 
Methods: Mucoadhesive tablets were formulated and optimized using a 23 factorial design and direct 
compression method. The independent variables were compression force and concentrations of 
chitosan and HPMC, while mucoadhesion time and in vitro drug release were dependent variables. 
Tablet characterization was carried out by evaluating hardness, thickness, tablet weight variation, 
content uniformity, friability and in vitro drug release at salivary pH (pH 6.8). 
Results: The tablets showed good mucoadhesion for an extended period (8 h), and their physical 
characteristics were within acceptable ranges. Drug release ranged from 60.5 % to 80.8 %. 
Conclusion: These results indicate that the mucoadhesive MCZ tablets formulated with chitosan and 
HPMC possess potential for the development of therapeutic preparations for management of 
oropharyngeal candidiasis. 
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Oral candidiasis or oropharyngeal candidiasis 
(OPC) is an infection of the mucous membrane 
of the mouth by Candida species of yeast [1]. 
Candida albicans, a normal component of the 
oral flora, is the most prominent causative agent 
of OPC. Oral candidiasis or oropharyngeal 
candidiasis (OPC) may be classified as primary, 
in which only the mouth and perioral tissues are 
involved, or secondary, in which other tissues 
are also infected [2,3].  
 
The oral route is the most acceptable and 
preferred route of administration of many drugs. 
However, first pass metabolism and enzymatic 
degradation constitute major challenges to oral 
drug delivery system. Thus the absorptive oral 
mucosa has become an attractive alternative 
site for drug delivery [4]. Mucoadhesive drug 
delivery systems overcomes some of the 
disadvantages associated with swallowing of 
drugs, and are important routes of 
administration of drugs in various dosage forms 
such as gels, ointments, patches and tablets [5]. 
 
Miconazole (MCZ) is a broad-spectrum 
antifungal agent and first-line antibiotic used for 
the prophylactic treatment of oral and vaginal 
candidiasis. It is available under the brand name 
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Daktarin®, an oral topical gel. The major 
disadvantage of this gel is that it must be 
applied three-to-four times a day for 14 days. 
The requirement for repeated administration 
leads to patient non-compliance. Furthermore, 
the rapid release of the drug from the gel 
causes a rapid decline in the drug concentration 
to sub-therapeutic levels [6]. Considering these 
drawbacks, there is a need for development of a 
sustained- or controlled-release buccal 
mucoadhesive formulation that can be applied 
locally or topically for treatment of oral 
candidiasis. To achieve better therapeutic effect 
it is necessary to attain adequate oral MCZ 






Miconazole (MCZ) was purchased from (Baoji, 
Shaanxi,Co. Ltd, China. Chitosan, HPMC 
microcrystalline cellulose (MCC), lactose, 
colloidal silicon dioxide, and magnesium 
stearate were products of Sigma Aldrich (St. 
Louis, MO, USA).  
 
23 factorial design for the development of 
mucoadhesive tablets 
 
Mucoadhesive (MCZ) tablets were developed 
with a full three-factor factorial design at two 
levels. The independent variables were the 
chitosan concentration (A), HPMC concentration 
(B), and compression force (C), while the 
dependent variables were the mucoadhesion 
time (Y1) and drug release from the tablets 
(Y2). Details of these variables, along with their 
corresponding high and low values, are 
presented in Table 1. Optimization of the 
formulation was carried out based on statistical 
analysis using a 23 full-factorial approach.  The 
interaction between the dependent and 
interdependent variables was determined by 
contour plots [7]. 
 
Table 1: Independent and Dependent Variables 
 
Variable Low Level  High Level  
Independent    
Chitosan 












% drug release (Y2)   
 
Preparation of mucoadhesive tablets 
 
Direct compression approach was used for the 
preparation of mucoadhesive tablets. Weighed 
quantities of ingredients were sifted through a # 
60 sieve to ensure homogeneity. The sifted 
material was then mixed uniformly. Round 16-
mm punch and die was used for the compression 
of the tablets. The weight of each tablet was 
adjusted to 200 mg. Table 2 summarizes the 
composition of all the batches of mucoadhesive 
tablets.  
 
Table 2: Formulation of mucoadhesive tablets 
 
 




This test was performed on 20 tablets by 
weighing individual tablets and calculating the 
average weight of the tablets [8]. The limit of 
weight variation was based on the US 
Pharmacopeial Convention (USP). 
 
Diameter and thickness 
 
Vernier caliper was used for the measurement of 
thickness and diameter at 3 different positions of 




Tablet hardness was assessed by Monsanto 
hardness test apparatus [8]. 
 
In vitro dissolution 
 
In vitro dissolution of mucoadhesive formulations 
was determined based on the solubility profile of 
the MCZ. The drug exhibited excellent solubility 
at higher pH. Hence dissolution was performed in 
a phosphate buffer of pH 6.8 at 37.0 ± 0.5 ºC 
using USP type II apparatus at 100 rpm. MCZ 
release was determined spectrophotometrically 
at 247.5 nm. Samples (5 ml) were withdrawn at 
specified time intervals and an equal volume of 
fresh buffer was added to the dissolution medium 
to maintain the sink condition. 
 
      
Code 
Factor                                  Response 
A B C Y1 Y2 
F1 −1 −1 −1 5.0 72.87 
F2 +1 −1 +1 4.0 60.54 
F3 −1 +1 −1 3.5 61.15 
F4 +1 +1 +1 5.5 73.80 
F5 +1 +1 −1 8.0 80.82 
F6 −1 +1 +1 7.5 66.54 
F7 −1 −1 −1 6.0 69.87 
F8 +1 −1 +1 6.5 72.35 
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Evaluation of in vitro mucoadhesion time 
 
Mucoadhesion time was determined on buccal 
mucosa isolated from a goat. The buccal mucosa 
was cleansed by rinsing it several times with 
physiological saline. A 5-cm patch of the mucosa 
was isolated and placed on a glass slide, and a 
tablet was placed on top of the mucosa. This 
slide was completely immersed in the saline 
solution, and the time required for the tablet to 





Design expert software (Version 6.0.8; Stat 
Ease.) was used for statistical analysis to 




Physicochemical characteristics of the 
tablets 
 
The results obtained from physical evaluation of 
the tablets are shown in Table 3. The diameter of 
the tablets ranged from 15.8 ± 0.5 to 16.3 ± 1.0 
mm, which were within acceptable range. There 
were no significant weight variations among the 
tablets (weights ranged from 198 ± 3 to 201 ± 3 
mg). The compression of tablets was carried out 
at 3-ton and 6-ton compression forces. Variations 
in hardness were observed due to difference in 
compression force during tablet compression. 
Batches with a 6-ton compression force had 
hardness ranging from 1.9 ± 1.0 to 3.1 ± 1.0 
kg/cm2. Greater hardness was found in tablets 
compressed with 6-ton force, when compared to 
batches subjected to 3-ton compression force 
(1.3 ± 1.0 to 1.6 ± 1.0 kg/cm2).  
 
A direct relationship was found between 
compression force and hardness of tablets. 
However, compression force was inversely 
related to tablet thickness. Batches with a 3-ton 
force had a higher thickness (3.2 ± 1.0 to 3.8 ± 
3.0 mm) than batches with 6 –ton force (2.9 ± 2.0 
to 3.1 ± 2.0 mm). Tablets compressed with 3-ton 
and 6-ton compression forces showed less than 
1% (w/w) friability, which is the acceptance 
criterion recommended by USP. Overall, all the 
formulations had pharmaceutically acceptable 
physical properties. 
 
From statistical analysis (Table 5), it was found 
that the selected model (2F1) was statistically 
significant based on model F-value of 223.78. 
The R2 value of 0.9798 for response Y2 points at 
2FI model (Table 4). In addition, factor Y1 was 
found to be statistically significant (p=0.0001), as 
shown in Table 4. 
 
 











F1 200.0 ± 3.0 5.0 ± 2.0 16.0 ± 1.0 2.0 ± 1.0 1.0 
F2 199.0 ± 3.0 4.8 ± 2.0 15.9 ± 0.0 1.8 ± 1.0 0.8 
F3 201.0 ± 1.0 4.9 ± 1.0 16.1 ± 2.0 2.2 ± 1.0 0.8 
F4 198.0 ± 2.0 5.2 ± 2.0 16.0 ± 1.0 1.7 ± 1.0 0.9 
F5 199.0 ± 3.0 5.3 ± 2.0 15.8 ± 1.0 1.7 ± 1.0 0.8 
F6 200.0 ± 1.0 5.5 ± 2.0 16.1 ± 1.0 2.8 ± 1.0 0.3 
F7 201.0 ± 2.0 5.7 ± 2.0 15.9 ± 2.0 2.4 ± 1.0 0.5 
F8 199.0 ± 3.0 3.5 ± 3.0 16.0 ± 1.0 1.4 ± 1.0 0.7 
 
Table 4: Regression analysis for responses Y1 and Y2 
 
Models R2 Adjusted R2 Predicted R2 SD Press Remarks 
Response Y1       
Linear 0.8021 0.7921 0.5217 3.63 22.20 ……… 
2FI 0.9987 0.9955 0.9865 1.74 55.00 Suggested 
Quadratic 0.6261 0.7172 0.7225 0.35 22.30  
Cubic 0.9120 0.6963 0.7912 2.63 49.20 ……… 
Response Y2       
Linear 0.6687 0.6262 0.7763 4.80 10.00 ……… 
2FI 0.9798 0.9720 0.9361 2.07 16.18 Suggested 
Quadratic 0.9011 0.8617 0.8488 3.97 10.00 ……… 
Cubic 0.9114 0.8625 0.8290 5.50 13.36 ……… 
Regression equations fitted to the models 
Y1 = + 54.66+27.34A+8.34B-7.33C 
Y2= +78.22 + 5.33 A-1.14B-2.14C 
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Table 5: Analysis of variance of Models Y1 and Y2 
 
Source DF Sum of squares Mean square F value P-value 
Model for Y1 3 3859.38 1286.46 512.35 <0.001 
A 1 3003.13 3003.13 961.00 0.0001 
B 1 153.12 153.12 49.00 0.002 
C 1 703.13 703.13 225.00 0.0011 
Model for Y2 3 409.74 136.58 223.78 0.0001 
A 1 300.74 300.74 264.73 0.0001 
B 1 33.17 33.17 29.20 0.0023 
C 1 75.83 75.83 66.75 0.0011 
 
 
Figure 1: Effect of (A) chitosan, (B) HPMC, and (C) compression force on tablet mucoadhesion. 
DR = Drug release 
 
 
Figure 2: Effect of (A) chitosan, (B) HPMC, and (C) compression force on tablet drug release 
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Figure 1 shows the effects of chitosan, HPMC 
and compression force (independent variables) 
on mucoadhesion time, while Figure 2 shows 




The in vitro mucoadhesion time of the tablets 
was determined at the salivary pH of 6.8 in 
phosphate-buffered saline. The mucoadhesive 
tablets showed increased mucoadhesion ranging 
from 2 to 8 h. Generally, increased 
mucoadhesion is preferred in this type of drug 
delivery system.  
 
Chitosan is the most widely used mucoadhesive 
polymer in the pharmaceutical industry, in 
various dosage forms such as transdermal 
bioadhesive patches, tablets, capsules, fast 
disintegrating films, and mucoadhesive films. 
Thus, chitosan was used chosen in this study for 
imparting mucoadhesive property to the tablets 
[10]. The contour plot obtained indicated that 
mucoadhesion time was significantly increased 
by increases in the concentration of chitosan. 
The increase in mucoadhesion period to 8 hours 
is suitable for treatment of patients with OPC. 
HPMC, a hydrophilic polymer with mucoadhesive 
properties, was used to improve the 
mucoadhesive properties of chitosan. It has been 
demonstrated that the combination of chitosan 
and HPMC is important for improving tablet 
mucoadhesion [11].  This is consistent with the 
contour plot obtained in the present study, which 
showed clearly that mucoadhesion was directly 
proportional to HPMC concentration. Obviously, 
the hydrophilic nature of the polymer imparted 
significant mucoadhesive properties on the tablet 
formulations. 
 
The increase in direct compression force from 3-
ton to 6-ton led to statistically significant increase 
in the mucoadhesion time of the tablets. The 
model F-value of 512.35 clearly shows that the 
2F1 model was statistically significant. Positive 
and negative coefficients from the equation 
indicate the synergistic and antagonistic effects 
of the variables respectively [9].  The suggested 
model for drug release Y2 was 2FI which had a 
correlation coefficient R2 of 0.9987. This model 
was also statistically significant, with all 
independent variables being statistically 
significant [A (p = 0.0001), B (p = 0.002), and C 
(p = 0.0011)]. 
 
Chitosan and HPMC had a combined effect on 
MCZ drug release from the mucoadhesive 
tablets. The contour plots revealed a significant 
and inverse relationship between chitosan and 
HPMC concentrations, and drug release from the 
tablets. Due to the controlled-release property of 
both chitosan and HPMC, and increase in 
compression force, MCZ drug release was 




Mucoadhesive tablets of MCZ formulated using 
chitosan and HPMC polymers significantly 
decreased drug release in the oral cavity. Thus, 
this formulation could be an efficient drug 
delivery technology for the treatment of OPC, 
since the increased mucoadhesion of the tablets 
would be helpful in retarding the progression of 
OPC. The results obtained in this study suggest 
that mucoadhesive drug delivery has a promising 
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